(NASDAQ: ARWR) Arrowhead Pharmaceuticals's forecast annual revenue growth rate of -6.02% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.75%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Arrowhead Pharmaceuticals's revenue in 2026 is $622,009,000.On average, 16 Wall Street analysts forecast ARWR's revenue for 2026 to be $65,636,554,646, with the lowest ARWR revenue forecast at $51,074,755,815, and the highest ARWR revenue forecast at $94,655,918,112. On average, 15 Wall Street analysts forecast ARWR's revenue for 2027 to be $44,038,947,616, with the lowest ARWR revenue forecast at $15,764,717,790, and the highest ARWR revenue forecast at $74,719,015,360.
In 2028, ARWR is forecast to generate $86,621,433,634 in revenue, with the lowest revenue forecast at $44,172,761,786 and the highest revenue forecast at $153,111,581,827.